A study evaluated the effectiveness of intramyocardial injection of allogeneic mesenchymal stem cells (MSCs) in pigs following myocardial infarction (MI). The study demonstrated that MSCs, derived from an allogeneic donor, were safely injected into the damaged myocardium three days after MI and resulted in long-term engraftment, reduced scar formation, and near-normalization of cardiac function. The cells were not rejected, making them a viable option for widespread application. The direct delivery of MSCs to the necrotic myocardium provided a valuable alternative to intracoronary cell injections and offered a strategy for cardiac regenerative therapy that avoids the need for autologous cell preparation. The study showed that MSCs engrafted in the myocardium, expressed cardiac myocyte proteins, and contributed to the regeneration of new myocardium. MSC treatment significantly reduced the percentage of the left ventricle occupied by fibrosis and improved cardiac function, including systolic and diastolic function. MRI and histological analyses confirmed the engraftment of MSCs and their ability to differentiate into cardiac myocytes and vascular endothelial cells. Additionally, MSC therapy improved myocardial efficiency, as evidenced by increased stroke work and decreased oxygen consumption. The study also found that MSCs reduced the size of the infarct and promoted the regeneration of viable myocardial tissue. These findings suggest that allogeneic MSCs can be safely and effectively used for cardiac repair after MI. The study highlights the potential of MSC therapy as a promising approach for treating myocardial infarction, with the ability to regenerate cardiac tissue and improve cardiac function. The results indicate that direct injection of MSCs into the damaged myocardium is a safe and effective method for cardiac repair.A study evaluated the effectiveness of intramyocardial injection of allogeneic mesenchymal stem cells (MSCs) in pigs following myocardial infarction (MI). The study demonstrated that MSCs, derived from an allogeneic donor, were safely injected into the damaged myocardium three days after MI and resulted in long-term engraftment, reduced scar formation, and near-normalization of cardiac function. The cells were not rejected, making them a viable option for widespread application. The direct delivery of MSCs to the necrotic myocardium provided a valuable alternative to intracoronary cell injections and offered a strategy for cardiac regenerative therapy that avoids the need for autologous cell preparation. The study showed that MSCs engrafted in the myocardium, expressed cardiac myocyte proteins, and contributed to the regeneration of new myocardium. MSC treatment significantly reduced the percentage of the left ventricle occupied by fibrosis and improved cardiac function, including systolic and diastolic function. MRI and histological analyses confirmed the engraftment of MSCs and their ability to differentiate into cardiac myocytes and vascular endothelial cells. Additionally, MSC therapy improved myocardial efficiency, as evidenced by increased stroke work and decreased oxygen consumption. The study also found that MSCs reduced the size of the infarct and promoted the regeneration of viable myocardial tissue. These findings suggest that allogeneic MSCs can be safely and effectively used for cardiac repair after MI. The study highlights the potential of MSC therapy as a promising approach for treating myocardial infarction, with the ability to regenerate cardiac tissue and improve cardiac function. The results indicate that direct injection of MSCs into the damaged myocardium is a safe and effective method for cardiac repair.